2022 - Research.com Best Scientist Award
Michael E. Thase focuses on Psychiatry, Depression, Major depressive disorder, Internal medicine and Randomized controlled trial. Many of his studies on Psychiatry apply to Clinical psychology as well. His Depression research incorporates elements of Psychotherapist, Imipramine, Pharmacotherapy and Cognition.
His Major depressive disorder research is multidisciplinary, relying on both Venlafaxine, Citalopram, STAR*D and Mood disorders. The study incorporates disciplines such as Placebo, Fluoxetine, Paroxetine, Sertraline and Reuptake inhibitor in addition to Internal medicine. Michael E. Thase focuses mostly in the field of Randomized controlled trial, narrowing it down to topics relating to Clinical trial and, in certain cases, Treatment-resistant depression.
Michael E. Thase mostly deals with Psychiatry, Depression, Major depressive disorder, Internal medicine and Clinical psychology. Within one scientific family, Michael E. Thase focuses on topics pertaining to Randomized controlled trial under Psychiatry, and may sometimes address concerns connected to Clinical trial. His Depression study incorporates themes from Rating scale, Cognition, Psychotherapist, Severity of illness and Comorbidity.
His Major depressive disorder study combines topics in areas such as Citalopram, Anesthesia and Major depressive episode. His Internal medicine research is multidisciplinary, incorporating perspectives in Venlafaxine, Placebo and Fluoxetine. His study looks at the intersection of Clinical psychology and topics like Cognitive therapy with Cognitive behavioral therapy.
The scientist’s investigation covers issues in Major depressive disorder, Depression, Psychiatry, Internal medicine and Clinical psychology. His research in Major depressive disorder intersects with topics in Clinical trial, Adverse effect, Randomized controlled trial, Placebo and Major depressive episode. His biological study spans a wide range of topics, including Physical therapy and Pharmacotherapy.
His work on Antidepressant, Bipolar disorder, Brexpiprazole and Anxiety as part of general Psychiatry study is frequently linked to Suicidal ideation, therefore connecting diverse disciplines of science. His study on Clinical endpoint, Tolerability and Post-hoc analysis is often connected to Pharmacogenomic Testing as part of broader study in Internal medicine. He has included themes like Insomnia, Interpersonal relationship, Cognition and Depressive symptoms in his Clinical psychology study.
His main research concerns Depression, Psychiatry, Major depressive disorder, Internal medicine and Bipolar disorder. His Depression research incorporates themes from Affect, Rating scale, Meta-analysis, Clinical psychology and PsycINFO. He performs multidisciplinary study on Psychiatry and Suicidal ideation in his works.
The various areas that Michael E. Thase examines in his Major depressive disorder study include Adjunctive treatment, Tolerability, Adverse effect, Cognitive behavioral therapy and Cognitive therapy. His studies deal with areas such as Placebo and Esketamine as well as Internal medicine. His Bipolar disorder research is multidisciplinary, incorporating elements of Lithium, Quetiapine, Mood, Ventral striatum and Mood disorders.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush;Madhukar H. Trivedi;Stephen R. Wisniewski;Andrew A. Nierenberg.
American Journal of Psychiatry (2006)
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
A.John Rush;Madhukar H Trivedi;Hicham M Ibrahim;Thomas J Carmody.
Biological Psychiatry (2003)
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.
Martin B. Keller;James P. McCullough;Daniel N. Klein;Bruce Arnow.
The New England Journal of Medicine (2000)
Five-Year Outcome for Maintenance Therapies in Recurrent Depression
David J. Kupfer;Ellen F. Frank;James M. Perel;Cleon Cornes.
Archives of General Psychiatry (1990)
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Alan J. Gelenberg;P. Freeman;John C. Markowitz;Jerrold F. Rosenbaum.
The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression
Robert M.A. Hirschfeld;Martin B. Keller;Susan Panico;Bernard S. Arons.
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder
Manuel A R Ferreira;Michael C O'Donovan;Yan A Meng;Ian R Jones.
Nature Genetics (2008)
Medication Augmentation after the Failure of Ssris for Depression
Madhukar H Trivedi;Maurizio Fava;Stephen R. Wisniewski;Michael E. Thase.
The New England Journal of Medicine (2006)
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
A. John Rush;Madhukar H. Trivedi;Stephen R. Wisniewski;Jonathan W. Stewart.
The New England Journal of Medicine (2006)
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Gary S. Sachs;Andrew A. Nierenberg;Joseph R. Calabrese;Lauren B. Marangell.
The New England Journal of Medicine (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: